BMY logo

Bristol-Myers Squibb Company (BMY)

$62.93

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on BMY

Market cap

$128.63B

EPS

4.52

P/E ratio

12.9

Price to sales

2.46

Dividend yield

4.004%

Beta

0.202074

Price on BMY

Previous close

$63.43

Today's open

$64.94

Day's range

$62.82 - $64.94

52 week range

$45.27 - $68.64

Profile about BMY

CEO

Christopher Boerner

Employees

32500

Headquarters

Princeton, NJ

Exchange

New York Stock Exchange

Shares outstanding

2.04B

Issue type

Common Stock

BMY industries and sectors

Healthcare

Pharmaceuticals

News on BMY

Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock

Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.

news source

Zacks Investment Research • 15 hours ago

news preview

Bristol Myers Squibb's Growth Portfolio Now Brings In $7.7 Billion a Quarter. Here's Why That Changes the Stock's Story.

Bristol Myers Squibb is a large and well-respected drug maker. The company is facing the normal industry headwind of patent expirations.

news source

The Motley Fool • Nov 14, 2026

news preview

Can BMY Sustain Growth in Its Cardiovascular Franchise?

Bristol Myers Squibb is expanding Camzyos??? reach, benefiting from Eliquis?

news source

Zacks Investment Research • Nov 13, 2026

news preview

14 dividend stocks selected for long-term growth

There are a variety of ways to select dividend stocks. John Buckingham, a veteran value-oriented stock picker, believes the best approach is to focus on a stock's total return potential, which means emphasizing long-term growth first, and income second.

news source

Market Watch • Nov 13, 2026

news preview

Bristol Myers to merge scientific, clinical teams under new R&D structure

Bristol Myers Squibb said on Thursday it will ​combine its scientific and ‌clinical expertise teams into an end-to-end research and development department ​under current Chief Medical ​Officer Cristian Massacesi, effective January ⁠1, 2027.

news source

Reuters • Nov 12, 2026

news preview

Bristol Myers Squibb Announces Evolution of Research & Development Organization

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Patients--Bristol Myers Squibb Announces Evolution of Research & Development Organization.

news source

Business Wire • Nov 12, 2026

news preview

Our Bristol Myers Squibb Stock Pick Is Up 35%. It's Still a Good Bet in Healthcare.

The stock is still attractive trading at 10 times forward earnings.

news source

Barrons • Nov 12, 2026

news preview

EXCLUSIVE: Lilly, Gilead Face Near-Term Drug Pricing Risks As Washington Turns Up Heat

The next wave of U.S. drug-price negotiations could put billions of dollars in pharmaceutical revenue under pressure, with Eli Lilly and Co (NYSE:LLY), Gilead Sciences, Inc. (NASDAQ:GILD) facing more immediate exposure and Merck & Co‘s (NYSE:MRK) and Bristol-Myers Squibb Co‘s (NYSE:BMY) confronting a potentially bigger test in the years ahead.

news source

Benzinga • Nov 11, 2026

news preview

Will Bristol Myers' Growth Brands Offset Eliquis Headwinds?

Bristol Myers' Growth Portfolio drives 57% of revenues, with key brands gaining traction to offset legacy drug declines and support growth.

news source

Zacks Investment Research • Nov 9, 2026

news preview

5 Defensive Dividend Stocks Yielding Up to 8.7% for Retirement Income

Recessions punish shaky payouts, but some companies keep collecting cash anyway. From power lines to pipelines to pill bottles, five low-beta names promise income, yet one of them runs coverage tighter than the rest.

news source

24/7 Wall Street • Nov 9, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Bristol-Myers Squibb Company

Open an M1 investment account to buy and sell Bristol-Myers Squibb Company commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in BMY on M1